Complete Research Bibliography

Ibogaine Studies 1962–2024

A comprehensive compilation of peer-reviewed research on ibogaine and iboga, covering addiction treatment, mental health applications, neuroplasticity mechanisms, and emerging therapeutic uses. All citations include direct links to PubMed or publisher sources.

Prepared by Iboga Healing Portugal
www.ibogahealingportugal.com

1. Addiction Treatment Research

Opioid Dependence

Brown TK, Alper K (2018). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse, 44(1), 24-36.

→ https://doi.org/10.1080/00952990.2017.1320802

Mash DC, Duque L, Page B, Allen-Ferdinand K (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Frontiers in Pharmacology, 9, 529.

→ https://doi.org/10.3389/fphar.2018.00529

Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J (1999). Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions, 8(3), 234-242.

→ https://doi.org/10.1080/105504999305848

Noller GE, Frampton CM, Yazar-Klosinski B (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse, 44(1), 37-46.

→ https://doi.org/10.1080/00952990.2017.1310218

Baumann MH, Pablo JP, Ali SF, Rothman RB, Mash DC (2000). Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Annals of the New York Academy of Sciences, 914, 354-368.

→ https://doi.org/10.1111/j.1749-6632.2000.tb05210.x

Stimulant Addiction (Cocaine, Amphetamines)

Lotsof HS, Alexander NE (2001). Case studies of ibogaine treatment: implications for patient management strategies. The Alkaloids. Chemistry and Biology, 56, 293-313.

→ https://doi.org/10.1016/s0099-9598(01)56020-4

Alper KR, Lotsof HS, Kaplan CD (2008). The ibogaine medical subculture. Journal of Ethnopharmacology, 115(1), 9-24.

→ https://doi.org/10.1016/j.jep.2007.08.034

Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V (2008). Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Human & Experimental Toxicology, 27(3), 181-194.

→ https://doi.org/10.1177/0960327107087802

Alcohol Dependence

Carnicella S, He DY, Yowell QV, Glick SD, Ron D (2010). Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addiction Biology, 15(4), 424-433.

→ https://doi.org/10.1111/j.1369-1600.2010.00251.x

He DY, Ron D (2006). Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB Journal, 20(13), 2420-2422.

→ https://doi.org/10.1096/fj.06-6394fje

General Addiction Treatment

Srivastava AB, Mariani JJ, Levin FR (2020). New directions in the treatment of opioid withdrawal. The Lancet, 395(10241), 1938-1948.

→ https://doi.org/10.1016/S0140-6736(20)30852-7

Mash DC, Kovera CA, Pablo J, et al. (2000). Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences, 914, 394-401.

→ https://doi.org/10.1111/j.1749-6632.2000.tb05213.x

2. Mental Health Research

Depression

Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL (1995). Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sciences, 57(3), PL45-PL50.

→ https://doi.org/10.1016/0024-3205(95)00273-9

Forsyth B, Machado L, Jowett T, Jakobi H, Garbe K, Winter H, Glue P (2016). Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of Ethnopharmacology, 189, 10-13.

→ https://doi.org/10.1016/j.jep.2016.05.022

PTSD and Trauma

Davis AK, Averill LA, Sepeda ND, Barsuglia JP, Amoroso T (2020). Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress, 4.

→ https://doi.org/10.1177/2470547020939564

Olszewski TM, Varrasse JF (2005). The neurobiology of PTSD: implications for nurses. Journal of Psychosocial Nursing and Mental Health Services, 43(6), 40-47.

→ https://doi.org/10.3928/02793695-20050601-09

3. Neuroplasticity & Neurotrophic Factors

Marton S, González B, Rodríguez-Bottero S, et al. (2019). Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits. Frontiers in Pharmacology, 10, 193.

→ https://doi.org/10.3389/fphar.2019.00193

Lu B, Bhave A (1997). Role of neurotrophins in synapse development and plasticity. Reviews in the Neurosciences, 8(1), 1-12.

→ https://doi.org/10.1515/revneuro.1997.8.1.1

Angelucci F, Ricci V, Pomponi M, et al. (2007). Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. Journal of Psychopharmacology, 21(8), 820-825.

→ https://doi.org/10.1177/0269881107078491

Zigova T, Pencea V, Wiegand SJ, Luskin MB (1998). Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Molecular and Cellular Neurosciences, 11(4), 234-245.

→ https://doi.org/10.1006/mcne.1998.0684

4. Traumatic Brain Injury Research

Cherian KN, Keynan JN, Anker L, et al. (2024). Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 30(2), 373-381.

→ https://doi.org/10.1038/s41591-023-02705-w

5. Mechanisms of Action

Bulling S, Schicker K, Zhang YW, et al. (2012). The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. The Journal of Biological Chemistry, 287(22), 18524-18534.

→ https://doi.org/10.1074/jbc.M112.343681

Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW (2002). Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. European Journal of Pharmacology, 438(1-2), 99-105.

→ https://doi.org/10.1016/s0014-2999(02)01284-0

Popik P, Layer RT, Fossom LH, et al. (1995). NMDA antagonist properties of the putative antiaddictive drug, ibogaine. The Journal of Pharmacology and Experimental Therapeutics, 275(2), 753-760.

→ PubMed: PMID 7473161

Baumann MH, Rothman RB, Pablo JP, Mash DC (2001). In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. The Journal of Pharmacology and Experimental Therapeutics, 297(2), 531-539.

→ PubMed: PMID 11303040

6. Neurodegenerative Disease Research

Peterson AL, Nutt JG (2008). Treatment of Parkinson's disease with trophic factors. Neurotherapeutics, 5(2), 270-280.

→ https://doi.org/10.1016/j.nurt.2008.02.003

Gill SS, Patel NK, Hotton GR, et al. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Medicine, 9(5), 589-595.

→ https://doi.org/10.1038/nm850

Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS (2005). Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nature Medicine, 11(7), 703-704.

→ https://doi.org/10.1038/nm0705-703

Oo TF, Kholodilov N, Burke RE (2003). Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. The Journal of Neuroscience, 23(12), 5141-5148.

→ https://doi.org/10.1523/JNEUROSCI.23-12-05141.2003

7. Autoimmune & Anti-Inflammatory Research

Jia J, Cheng J, Wang C, Zhen X (2018). Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Frontiers in Cellular Neuroscience, 12, 314.

→ https://doi.org/10.3389/fncel.2018.00314

Oxombre B, Lee-Chang C, Duhamel A, et al. (2015). High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 172(7), 1769-1782.

→ https://doi.org/10.1111/bph.13037

Thompson C, Szabo A (2020). Psychedelics as a novel approach to treating autoimmune conditions. Immunology Letters, 228, 45-54.

→ https://doi.org/10.1016/j.imlet.2020.10.001

8. Antimicrobial Research

Rastogi N, Abaul J, Goh KS, et al. (1998). Antimycobacterial activity of chemically defined natural substances from the Caribbean flora in Guadeloupe. FEMS Immunology and Medical Microbiology, 20(4), 267-273.

→ https://doi.org/10.1111/j.1574-695X.1998.tb01136.x

Silva EM, Cirne-Santos CC, Frugulhetti IC, et al. (2004). Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine. Planta Medica, 70(9), 808-812.

→ https://doi.org/10.1055/s-2004-827227

Yordanov M, Dimitrova P, Patkar S, Saso L, Ivanovska N (2008). Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection. Canadian Journal of Microbiology, 54(6), 435-440.

→ https://doi.org/10.1139/w08-029

Yordanov M, Dimitrova P, Patkar S, et al. (2005). Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections. Journal of Medical Microbiology, 54(Pt 7), 647-653.

→ https://doi.org/10.1099/jmm.0.45919-0
